<DOC>
	<DOCNO>NCT01220492</DOCNO>
	<brief_summary>Liver cirrhosis ( LC ) represent late stage progressive hepatic fibrosis characterize distortion hepatic architecture formation regenerative nodule . The liver transplantation one effective therapy available patient . However , lack donor , surgical complication , rejection , high cost ` serious problem . The potential stem cell differentiate hepatocytes cell recently confirm . Particularly , autologous bone marrow-derived mesenchymal stem cell ( BM-MSC ) demonstrate decrease MELD score increase serum albumin 4 patient decompensated liver cirrhosis . Therefore , investigator propose hypothesis umbilical cord-derived MSCs ( UC-MSC ) also improve disease condition LC patient , particularly reduce decompensated condition patient .</brief_summary>
	<brief_title>Umbilical Cord Mesenchymal Stem Cells Patients With Liver Cirrhosis</brief_title>
	<detailed_description>Liver cirrhosis ( LC ) represent late stage progressive hepatic fibrosis characterize distortion hepatic architecture formation regenerative nodule . The liver transplantation one effective therapy available patient . However , lack donor , surgical complication , rejection , high cost ` serious problem . The potential stem cell differentiate hepatocytes cell recently confirm . In particular , bone marrow-derived mesenchymal stem cell ( BM-MSC ) transplantation applicated clinic treat several human disease GVHD , cardiac injury brain injury , display good tolerance efficiency . BM-MSC also use treat human liver diseases liver failure liver cirrhosis . In phase 1 study , autologous BM-MSC transplantation potential decrease MELD score increase serum albumin 4 patient decompensated liver cirrhosis . The purpose study learn whether umbilical cord-derived MSCs ( UC-MSC ) improve disease condition patient liver cirrhosis . This study also look well BM-MSC tolerate safety LC patient . Participants study randomly assign one two treatment arm : Arm A : Participants receive 8 week conserve treatment plus UC-MSC treatment . Arm B : Participants receive 8 week conserve treatment plus saline . UC-MSC prepared accord standard procedure collect plastic bag contain anti coagulant . MSCs give via i.v . sonography monitoring . After cell therapy , patient follow week 4 , 8 , 12 , 24 , 36 48 . The evaluation clinical parameter level ascites volume ascites disappearance rate , serum alanine aminotransferase ( ALT ) , total bilirubin ( TB ) , prothrombin time ( PT ) , albumin ( ALB ) , prealbumin ( PA ) , rountin blood test , renal function test detect timepoints . MELD-Na score clinical symptom well complication also observe simultaneously .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<criteria>1 . Liver cirrhosis 2 . Negative pregnancy test ( female patient fertile age ) 3. write consent 1 . Hepatocellular carcinoma malignancy 2 . Pregnancy 3. sepsis 4 . Presence significant extrahepatic biliary disease ( e.g . CBD stone , PSC , etc . ) 5 . Cardiac , renal respiratory failure 6 . Active thrombosis portal hepatic vein</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>liver cirrhosis</keyword>
	<keyword>mesenchymal stem cell</keyword>
	<keyword>ascites</keyword>
	<keyword>serum albumin</keyword>
</DOC>